CAS Number: 154229-18-2
Therapeutic Category
Anti-Cancer/ Oncology
API Technology
Steroid
Dose Form
Oral Solids
Innovator Brand (USA)
Zytiga
Available Regulatory Filing
USA
Canada
Australia
Saudi Arabia
Taiwan
Russia
Malaysia
South Africa
Turkey
Europe
Brazil
China
Mechanism of Action
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism.
Indication
ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with
- Metastatic castration-resistant prostate cancer (CRPC).
- Metastatic high-risk castration-sensitive prostate cancer (CSPC)